MENU
BAX
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

BAX stock forecast, quote, news & analysis

Baxter offers a variety of medical supplies and equipment to providers... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
BAX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BAX with price predictions
Oct 14, 2026

BAX's RSI Oscillator recovers from oversold territory

The RSI Indicator for BAX moved out of oversold territory on September 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 28 of the 43 cases the stock moved higher. This puts the odds of a move higher at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 55 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 25 of 46 cases over the following month. The odds of a continued upward trend are 54%.

Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 165 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

BAX moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BAX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

BAX broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BAX entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.957) is normal, around the industry mean (5.011). P/E Ratio (87.846) is within average values for comparable stocks, (163.451). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.456). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.074).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Dividends

BAX paid dividends on October 01, 2026

Baxter International BAX Stock Dividends
А dividend of $0.01 per share was paid with a record date of October 01, 2026, and an ex-dividend date of August 28, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.89B. The market cap for tickers in the group ranges from 126 to 146.54B. ISRG holds the highest valuation in this group at 146.54B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 6%. NXGL experienced the highest price growth at 54%, while NNNN experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 82%. For the same stocks of the Industry, the average monthly volume growth was 76% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 58
Price Growth Rating: 53
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
One Baxter Parkway
Phone
+1 224 948-2000
Employees
37500
Web
https://www.baxter.com
BAX's RSI Oscillator recovers from oversold territory